Introduction {#Sec1}
============

Primary spinal cord tumors (PSCT) are rare central nervous system (CNS) neoplasms in childhood that occur at a frequency of 0.19 per 100,000 person-years according to the Central Brain Tumor Registry of the United States \[[@CR1]\]. The incidence varies by age, and increases 1.6 times from 0--4 years old (0.17 per 100,000 person-years) to ages 15--19 (0.28 per 100,000 person-years) \[[@CR1]\]. Pediatric PSCT account for \<6% of all CNS tumors \[[@CR2]\], and have a roughly similar male to female predominance \[[@CR3]--[@CR5]\]. The initial approach to diagnosis and management of PSCT has been extensively reviewed \[[@CR2], [@CR6], [@CR8]--[@CR21]\] and is dependent on anatomical location (intramedullary, extramedullary intradural, and extradural) and pathology. Much of our understanding of the clinical presentation, diagnosis, treatment, and survival features of PSCT comes from small series of patients due to the low incidence. A few larger series of combined multi-institutional PSCT patients have been reported according to specific tumor type \[[@CR2], [@CR17], [@CR22]\]. Several smaller pediatric series of PSCT have been published correlating presentation, treatment, and tumor histology with event free and overall survival \[[@CR10], [@CR12], [@CR13], [@CR18], [@CR20], [@CR23]--[@CR27]\]. To our knowledge, no series has specifically attempted to correlate duration of symptoms, neurological examination abnormalities, and specific neuroradiographic features with malignancy and overall survival. To address these issues, we have performed a retrospective analysis of all previously healthy pediatric patients seen at our institution from 1995 to present with newly diagnosed PSCT. The diverse presentations, duration of symptoms, radiographic findings, and outcomes presented in our series expands our current knowledge of this rare pediatric neoplasm.

Methods {#Sec2}
=======

Clinical information {#Sec3}
--------------------

All spinal cord tissue specimens at Children's National Medical Center in Washington, DC, from 1995 to present were available for retrospective analysis and approved by the Institutional Review Board. A total of 45 patients were identified with spinal cord lesions diagnosed between 1995 and present. Neurodevelopmental tumors (dermoids, epidermoids, and teratomas), lesions associated with tethered cord (lipomas, fibrous bands, hemartomatous tissue, and fibrolipomatosis), sacrococcygeal teratomas, epidermoid cysts, and tumors related to neurofibromatosis Type 1 or Type 2 were excluded from the study. Patients with non-PSCT (i.e. drop metastasis from brain neoplasms) were excluded from the analysis. No patients in our study had meningiomas or schwanommas that were not associated with Neurofibromatosis. Of the 45 total spinal cord samples, 25 patients were diagnosed with PSCT and were available for analysis. Information including age, sex, presenting symptoms, duration of symptoms, neurological examination, and treatment were collected and utilized in the overall clinical analysis.

Neuroradiographic investigation {#Sec4}
-------------------------------

Standard MRI sequences of pediatric spinal cord tumors using a 1.5-T magnet were reviewed by three non-blinded pediatric neuroradiologists (NK, AZ, and GV). Of the 25 patients with available clinical information, 20 patients had complete imaging studies available for analysis. The following neuroimaging features were used for quantitative analysis: tumor location, size, contrast enhancement, and presence of edema. Tumor volume was measured in depth, height, and width. Volume (mm^3^) was calculated as: depth × height × width × 0.5 and grouped in subcategories of small (≤1,000 mm^3^), medium (1,001--9,999 mm^3^), and large (≥10,000 mm^3^) for statistical analysis.

Pathological investigation {#Sec5}
--------------------------

All pathology diagnosis were made by a pediatric neuropathologist. Select cases used for the clinical and radiographic analysis were re-reviewed by two pediatric neuropathologists (MS, EJR). Hematoxylin and eosin stained sections were re-reviewed as were other routine histochemical and immunohistochemical preparations. Neoplasms were classified and graded based on World Health Organization criteria.

Statistical analysis {#Sec6}
--------------------

Data were analyzed using Fisher's exact test to compare proportions, and *t*-test for independent samples to compare means. Kaplan--Meier Survival and ANOVA analysis were performed using GraphPad 5.0 Software (San Diego, CA). Stratified Kaplan--Meier analysis was performed using SPSS software (Chicago IL).

Results {#Sec7}
=======

Clinical features of primary spinal cord tumors of childhood {#Sec8}
------------------------------------------------------------

We retrospectively reviewed the records of 25 consecutive pediatric patients seen at a single institution from 1995 to present newly diagnosed with PSCT. As summarized in Table [1](#Tab1){ref-type="table"}, the average age at presentation was 7.9 months (range 1--5 years; 15 boys). Thoracic cord was the most commonly involved location (*N* = 17) followed by cervical (*N* = 9), lumbar (*N* = 7), and sacral/cauda equina (*N* = 7). The most common presenting features were back pain (15/25) and weakness (13/25). In children less than 3 years old, head tilt, delayed motor milestones, and early handedness were the predominant presenting symptoms. There was no difference between age of presentation and symptoms of pain and weakness (*P* = 0.17), however, specific neck complaints including pain, weakness, rigidity, or tremor were significantly observed in younger patients (average 2.5 years; range 1.5--5 years) (*P* = 0.05). The average reported duration of symptoms was 7.8 months, ranging from 1 week (acute lower extremity pain/weakness) to 5 years (chronic low back pain). There was no significant difference between duration of symptoms and symptom type (*P* = 0.06), but early handedness and back pain were present the longest prior to diagnosis (Fig. [1](#Fig1){ref-type="fig"}). There was no correlation between symptom duration and age of presentation (*P* = 0.95). When stratified according to specific age groups (0--3 years, 4--12 years, and 13--18 years) duration of symptoms were not different (*P* = 0.11). Boys had a longer reported duration of symptoms prior to diagnosis than girls (11.3 vs. 2.9 months) (*P* = 0.03). While there was no correlation between length of presenting symptoms and anatomical location (*P* = 0.30), there was a difference between length of symptoms and tumor grade. Patients with high grade tumors had a shorter duration of symptoms (average 1.65 months, range 0.25--7 months) than patients with low grade tumors (average 11.1 months, range 0.25--60 months) (*P* = 0.05). There was no difference between tumor grade and age (*P* = 0.71) or gender (*P* = 0.10). The most common neurological abnormality was change in muscle tone or strength, followed by abnormal reflexes (7 hyper, 9 hypo/absent). Four patients had evidence of a sensory level on examination along with hypo or absent reflexes, mimicking transverse myelitis or Guillain Barré syndrome.Table 1Clinical features of primary spinal cord tumors (PSCT) of childhoodPtAge at diagnosis (years)SexSymptom duration (months)Chief complaintPhysical exam abnormalitiesSpinal levelPathology diagnosisTreatment^a^Progressive diseaseSurvivalSCXRT113M5Right extremity weaknessRUE/RLE weakness, atrophy, fasciculations, shoulder dropC5--T2Pilocytic astrocytomaGTNoYesNoYes211M7Lower back pain, difficulty ambulatingMinimal hip flexion weakness bilaterallyL4--S2Anaplastic ependymomaGTNoYesYesYes314M24Low back pain, difficulty ambulatingRLE weakness, dermatomal sensory loss, decreased reflexesT8--L2Pilocytic astrocytomaGTNoNoNoYes45M0.5Left extremity weakness, neck painLUE proximal \> distal weakness, normal sensation/reflexesC1--C5Anaplastic astrocytomaSTYesYesYesNo515F1Back pain, left lower extremity weaknessLLE weakness, hyperreflexia, BabinskiT8--T10Glioblastoma multiformeSTYesYesYesNo69M18Back PainMinimal LLE weaknessT4--T10Fibrillary astrocytomaSTYesYesYesNo75F0.25Toe walkingLLE weakness, absent rectal toneL3--L5Lymphoblastic lymphomaBYesNoNoYes811M0.75Difficulty ambulatingBilateral LE weakness, hyperreflexia, clonus, BabinskiT3--T5Langerhans cell histiocytosisGTYesNoNoYes96M0.25Leg pain, abdominal painBilateral proximal LE weakness, areflexia, sensory levelT11Primitive neuroepithelial tumorBYesYesYesNo100.75F0.25Bilateral lower extremity weaknessBilateral LE plegia, areflexia, sensory level, decreased rectal toneT12--S5Primitive undifferentiated neoplasmSTNoYesYesNo1111M4Back painBilateral LE weakness, areflexiaL2--L3EpendymomaGTNoNoNoYes121.5F0.5Refusal to walk, neck stiffnessHead tilt, nuchal rigidity, minimal LUE weaknessC3--T1Fibrillary astrocytomaSTYesYesYesYes131.5F4Neck stiffnessIncreased tone neck flexorsC1--C7Pilocytic astrocytomaSTYesNoYesYes141F13Early handedness, delayed motor milestonesMild R hemiparesis, hyperreflexia, increased toneMidbrain-C5Pilocytic astrocytomaBYesNoYesNo155F2Urinary incontinence, difficulty ambulatingBilateral LE weakness, decreased rectal toneS1--5EpendymomaBYesYesYesNo1617M1Back pain, lower extremity weakness, constipationBilateral LE weakness, hyperreflexia, Babinski, deceased rectal toneThoracic cord holosyrinxPilocytic AstrocytomaSTYesYesNoNo1717M12Back painBilateral hip flexion weaknessCauda equinaMyxopapillary ependymomaGTNoYesNoYes182.5M7Nuchal tremorHead tilt, decreased tone bilateral UE, depressed reflexes, decreased strengthT1--T6Diffuse fibrillary astrocytomaGTNoYesNoYes191F0.25Progressive LE weaknessLE plegia, areflexia, absent sensation, absent rectal toneC1--S5Embryonal tumorSTYesNoYesNo2017M60Intermittent low back pain, R thigh radicular painHip flexion weakness, patellar hyperreflexiaL2-cauda equinaEpendymoma with myxopapillary featuresGTNoNoNoYes2110M3Lower back painLE weakness, hyperreflexia, Babinski, Sensory level up to T8, decreased rectal toneT5Primitive Neuroepithelial tumorSTYesYesYesNo220.75F4Early handedness, head tiltHead tilt, RUE weakness, hyperreflexiaC2--T2Glioblastoma multiformeSTYesYesYesYes239M12Difficulty with ambulationLE dorsiflexion/plantar flexion weakness, R patellar hyporeflexia, bilateral BabsinkiT9--L1Fibrillary astrocytomaSTNoYesNoYes248F0.25Back pain, LE weaknessLE weakness, hypotonia, areflexia, absent rectal toneL3--L5EpendymomaGTYesYesYesYes257M15Neck painRUE hemiatrophy, minimal weakness, depressed reflexesMedulla-T1Pilocytic astrocytomaSTNoNoNoYes*S* Surgery, *C* chemotherapy, *XRT* radiation therapy, *GT* gross total resection, *ST* subtotal resection, *B* biopsyFig. 1Average duration of symptoms of primary spinal cord tumors (PSCT) of childhood. The average duration of neurological complaints of PSCT is shown. There was no significant difference between specific symptom type and duration by ANOVA analysis (*P* = 0.063)

### Neuroradiographic analysis of primary spinal cord tumors of childhood {#Sec9}

We performed a detailed neuroradiographic analysis including tumor volume, T1/T2 signal characteristics, gadolinium enhancement patterns, and the presence of edema in 20 patients with newly diagnosed PSCT who had sufficient image sequences for interpretation. Typical and atypical neuroradiographic features of spinal cord astrocytomas and ependymomas, the most common tumors in our series, are illustrated in Fig. [2](#Fig2){ref-type="fig"}. As summarized in Table [2](#Tab2){ref-type="table"}, the most common spinal tumor location was intramedullary (*N* = 11) followed by extramedullary intradural (*N* = 8) and epidural (*N* = 1). Eighty percent (4/5) of ependymomas analyzed in our series had an extramedullary component; half of which had multiple lesions. Quantitative volumetric analysis revealed ranges from 98 to 94,080 mm^3^ (average 19,474 mm^3^). There was no difference between low grade tumor volume (average 19,868 mm^3^) and high grade tumor volume (average 15,676 mm^3^) (*P* = 0.63) at the time of diagnosis. When stratifying for evidence of edema (illustrated in Fig. [3](#Fig3){ref-type="fig"}), there was no correlation with tumor grade (*P* = 0.22). Likewise, neither T2 hyperintensity (*P* = 1.0) nor T1 hypointensity (*P* = 0.11) were significantly associated with grade. Homogeneous gadolinium enhancement was found significantly more in low grade tumors (*P* = 0.003). Rim gadolinium enhancement, on the other hand, did not correlate with tumor grade (*P* = 0.098).Fig. 2MRI characteristics of glial and ependymal primary spinal cord tumors (PSCT). *Top panel***a** Pediatric spinal cord astrocytomas. *A*--*E* Pilocytic astrocytoma. Note the wide variability of imaging features. All lesions *A*--*E* are well-defined on T2 (T1)-weighted images. Only *A* and *E* have appearance of nodular enhancement in conjunction with a cyst, no cysts are seen in lesions *B*, *C*, *D*. The enhancement patterns vary from irregular (*A*, *E*), homogeneous (*B*), no significant enhancement (*C*) to rim-enhancement (*D*), the latter usually more typical of a higher grade lesions. *F*+*G* Fibrillary astrocytoma. These lesions share a pattern of sausage-like expansion of the spinal cord, similar to pilocytic astrocytoma *C*, but with diffuse contrast enhancement. Edema of the adjacent spinal cord is only seen in lesion *F*. *H*+*I* Anaplastic (*H*) and high-grade (*I*) astrocytoma. Both high grade astrocytomas are rim-enhancing; edema of the adjacent spinal cord is more prominent in *I* when compared to *H*. *Bottom panel***b**. Pediatric spinal cord ependymoma. Sagittal T1, T2, and axial T2 are shown in *A*--*C* compared to a patient with myxopapillary ependymoma in *D*. These lesions are only different in the T2 appearance (bright in patient *D*) and inhomogeneous contrast enhancement in patient *D*. Interestingly, 2/5 patients presented with multiple lesions (patients *B*+*E*)Table 2Radiographic features of primary spinal cord tumors (PSCT) of childhoodPathologySpinal levelTumor locationTumor volume (mm3)MRI signal^a^Gadolinium enhancementEdemaT1T21Pilocytic astrocytomaC5--T1Intramedullary21,660↓↔IrregularNo2Pilocytic astrocytomaC1--C3Intramedullary12,000↔↓↑HomogenousNo3Anaplastic ependymomaS2Extramedullary\
Intradural2,211↓↔HomogenousYes4Anaplastic astrocytomaC2--C5Intramedullary11,832↓↓↑Rim enhancingYes5Langerhans cell histiocytosisT4Epidural11,160↔↔Not performedNo6Primitive neuroepithelial tumorT8--T12Intramedullary6,600↓↑↓↑IrregularYes7Primitive neuroectodermal tumorS3Extramedullary\
Intradural1,056↔↓↑Not performedNo8Primitive undifferentiated tumorT10--S1Extramedullary\
Intradural13,520↓↓↑IrregularYes9EpendymomaL2--L3Extramedullary\
Intradural11,856↓↑HomogenousNo10Fibrillary astrocytomaC3--T1Intramedullary21,504↓↑IrregularNo11Pilocytic astrocytomaC1--C7Intramedullary21,560↓↑IrregularYes12Pilocytic astrocytomaC1--C5Intramedullary94,080↓↑IrregularNo13Myxopapillary ependymomaL1--S1Extramedullary\
Intradural21,630↓↑IrregularNo14Pilocytic astrocytomaT7--T8Intramedullary98↔↓↑HomogenousNo15Fibrillary astrocytomaT1--T6Intramedullary21,097↓↑IrregularYes16Embryonal tumorC5--S2Extramedullary Intradural70,200↓↔IrregularNo17Ependymoma with myxopapillary featuresL2Extramedullary\
Intradural2,736↓↑IrregularNo18Glioblastoma multiformeC2--T2Intramedullary4,212↓↑Rim enhancingYes19EpendymomaL3--L5Intramedullary4,920↓↑HomogenousNo20Pilocytic astrocytomaC1--T1Intramedullary35,552↓↑IrregularYes*C* Cervical, *T* Thoracic, *L* Lumbar, *S* Sacral^a^↑, Hyperintense;↓, hypointense; ↔, isointenseFig. 3Detection of spinal cord tumor-related edema on MRI. Examples of the presence or absence of edema in two cases of pilocytic astrocytoma are shown. **a***Edema present* Note the small central rim-enhancing lesions surrounded by bright T2 (*top*) and dark T1 (*bottom*) signal, compatible with edema. **b***Edema absent* Note there is no increased T2 (*top*) or dark T1 (*bottom*) signal beyond the well-defined border of this lesion

Effects of symptomatology and treatment on survival {#Sec10}
---------------------------------------------------

The median overall survival of our series of PSCT was 53 months (range 1.5--53 months; 10 deaths) with a median follow up 21 months (Fig. [4](#Fig4){ref-type="fig"}). Despite the earlier presentation of girls in our series, there was no affect of gender on survival (Median survival 53 months boys; 41 months girls) (*P* = 0.58) (Fig. [4](#Fig4){ref-type="fig"}a). There was no correlation between age of diagnosis and survival (*P* = 0.35), nor was there a difference when stratified according to specific age group (*P* = 0.79) (Fig. [4](#Fig4){ref-type="fig"}b). Duration of symptoms did not affect overall survival; given the wide range of presenting neurological symptoms. Those patients with symptoms greater than 6 months had an average survival of 48 months compared to 35 months for symptoms greater than 6 months (*P* = 0.91) (Fig. [4](#Fig4){ref-type="fig"}c). Of the 10 deaths in our series, the average time of presentation was 3.9 months compared to 10.4 months for those who survived (*P* = 0.08). As expected, patients with high grade tumors (median survival 25 months) had significantly poorer survival than those with low grade tumors (median survival 53 months) (*P* = 0.05) as shown in Fig. [4](#Fig4){ref-type="fig"}d. In addition to having no correlation with tumor grade, tumor volume did not correlate with overall survival in our series (*P* = 0.13).Fig. 4The effects of symptomatology, tumor grade, and treatment on overall survival of pediatric primary spinal cord tumors. Kaplan--Meier survival analysis was stratified according to gender (**a**), age (**b**), duration of symptoms (**c**) tumor grade (**d**), extent of resection (**e**), and adjuvant therapies (**f**). There was no correlation between overall survival and gender (*P* = 0.58), age (*P* = 0.79), or duration of symptoms greater or less than 6 months (*P* = 0.91). High grade malignancy was associated with poorer survival (*P* = 0.05) as was gross total resection (*P* = 0.01). Adjuvant chemotherapy and radiation therapy, either alone or in combination, had no effect on overall survival in our series (*P* = 0.31)

Compared to patients with biopsy or subtotal resection, patients with gross total resection had 100% survival (Fig. [4](#Fig4){ref-type="fig"}e) (*P* = 0.01). Thirty-six percent of patients in our series had a gross total resection (9/25). Of these patients, three had residual post operative weakness. Of the 25 patients with surgical intervention (gross/subtotal resection, biopsy) 10 had some degree of post operative weakness, 8 of which resolved within months of surgery. The most severe complication was the development of Brown-Sequard syndrome in a patient with a lumbar sacral diffuse fibrillary astrocytoma.

Since non-surgical adjuvant treatments were not standardized, a generalized stratification of chemotherapy, radiation, or combined therapies were used for survival analysis. Three of 25 patients had adjuvant chemotherapy alone without evidence of relapse. Six of 25 had adjuvant radiation therapy alone (two fibrillary astrocytoma, one anaplastic astrocytoma, one pilocytic astrocytoma, one PNET, one myxopapillary ependymoma); of these two had progressive disease. Combined radiation and chemotherapy were used in 40% of patients (10/25), 90% of whom had either metastatic disease at diagnosis or eventually had progressive disease. As shown in Fig. [4](#Fig4){ref-type="fig"}f, adjuvant chemotherapy and radiation either alone or in combination had no significant effect on overall survival (*P* = 0.31). While the specific cause of death was not known for each of the 10 patients, 4 had complications secondary to pneumonia and sepsis.

Discussion {#Sec11}
==========

The average duration of presenting symptoms of 7.8 months in our series of PSCT is similar to previous reports ranging from 2 to 9 months \[[@CR18], [@CR21], [@CR22]\]. Bouffet et al. reported 11% (8/73) of patients with primary spinal astrocytomas had greater than 3 years of symptoms prior to presentation. While pain and weakness were the predominant presenting features in many patients, more subtle findings such as early handedness can delay diagnosis particularly in younger patients. A common set of presenting complaints among younger patients in our series involved the neck and included pain and torticollis, as has been reported in two younger patients with PSCT \[[@CR28]\]. In older patients, chronic back pain has been associated with delayed diagnosis of PSCT \[[@CR22], [@CR23]\], similar to our findings. The variability of reflexes (hypo/hyper/absent) on neurological examination was not particularly helpful in establishing tumor location or grade compared to more sensitive findings of tone and strength. Ultimately, duration of presenting symptoms did not correlate with outcome as has been reported \[[@CR23]\]. However, shorter duration of symptoms is associated with higher grade tumors in our series and has been associated with poor survival in the series reported by Bouffet et al. \[[@CR22]\].

One of the strengths of the current study is the detailed radiographic analysis performed on a subset of patients where neuroimaging studies were complete. It seems counterintuitive that there was no correlation between tumor volume and tumor type, grade, or survival. This suggests that tumor location itself as opposed to size may be an important factor in achieving gross total resection and hence improved survival. One set of factors that may associated with spinal cord tumor grade are specific patterns of gadolinium enhancement. Our observations of homogeneous gadolinium enhancement associated with low grade tumors has been reported \[[@CR29]\]. However, in the context of predictors of survival, this may be an important finding. Due to our small number of patients studied, it is difficult to make generalizations. A multi-institutional series of collaborative neuroradiographic data on PSCT is ultimately necessary to validate our results.

One of the major factors associated with survival in our series of PSCT was degree of surgical resection. While 35% of PSCT are intramedullary (65% in our series), making total resection at times technically challenging, it is a feasible option \[[@CR7], [@CR14], [@CR30]--[@CR33]\]. However, as reported in our series, post operative complications, although temporary, can be associated with significant morbidity. Radical excision of intramedullary tumors has been reportedly associated with both an increase in survival and improved quality of life \[[@CR6], [@CR31]--[@CR34]\], but are dependent on tumor type and grade. Long term control or cure can be achieved for some intramedullary ependymomas by total/subtotal resection alone \[[@CR9], [@CR11], [@CR17], [@CR21]\]. This is in contrast to infiltrating astrocytomas where the role of subtotal resection is less clear \[[@CR4], [@CR9], [@CR17], [@CR21], [@CR31]\] but may be better than biopsy alone \[[@CR35]\]. Only through collaborative studies involving large number of patients will we be able to meaningfully assess the extent of surgical resection on survival.

One of the major criticisms of the current study in addition to the small sample size and retrospective study design, is the lack of uniformity of adjuvant therapies. While neither chemotherapy nor radiation alone or in combination affected overall survival in our series, there remains great debate regarding the role of adjuvant therapies in PSCT. There are some who avoid adjuvant therapy in cases of total resection \[[@CR36], [@CR37]\]. In the case of radiation therapy, favorable outcome results have been reported in patients with low grade spinal astrocytomas and ependymomas \[[@CR38]--[@CR44]\]. However, in patients with low grade astrocytomas with incomplete resection, the role of radiation therapy is unclear \[[@CR22]\]. With regards to adjuvant chemotherapy, there is no proven efficacious regimen for any given pathological subtype or location.

A major hurdle in our understanding of PSCT, is a lack of fundamental knowledge of the biology of the tumor. It is naïve to assume the biological pathways that govern oncogenesis in the brain can be applied to the spinal cord. Furthermore, small amounts of tissue obtained during biopsy or resection can limit the number of non standard genetic/biochemical tests necessary to fully understand the biology of the tumors. While fortunately the incidence if PSCT is quite low, the mortality associated with PSCT calls for a more collaborative approach to our understanding and treatment of pediatric spinal cord tumors.
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